argenx Acquires Forte Biosciences for $2.2 Billion: A New Immunology Play

argenx is buying Forte Biosciences for $2.2 Billion in cash, aiming to add a clinically proven asset in vitiligo and celiac disease to its pipeline.

argenx’s Strategic Play: $2.2 Billion Cash Deal

argenx SE (NASDAQ:ARGX) signed a definitive agreement on July 27 to purchase Forte Biosciences, Inc. (NASDAQ:FBRX) at $77 per share. The offer represented a 40% premium to the pre‑announcement closing price, but when measured against the volume‑weighted average price after Forte’s Phase 1b vitiligo readout, the premium swelled to 86%.

Forte’s FB102: A Breakthrough in Vitiligo and Celiac

FB102 is a first‑in‑class anti‑CD122 antibody that delivered a 29.6% mean improvement on the Facial Vitiligo Area Scoring Index over 24 weeks, separating from placebo by day 64. This clinical signal positions the asset as a catalyst in the shift toward large‑molecule immunology platforms.

Financial Backbone: Cash Strength and Revenue Surge

argenx reported $1.3 Billion net product sales in Q1 2026 (up 63% YoY) and a $366 Million net profit. The balance sheet boasts $4.9 Billion in cash and financial assets, providing ample liquidity for a sizable cash acquisition.

Concentration Risk and Diversification Imperative

Growth has been driven almost exclusively by Vyvgart, the blockbuster FcRn‑blocking therapy now in its 17th consecutive quarter of expansion. CEO Karen Massey’s “Vision 2030” roadmap targets 50,000 patients across ten indications, underscoring the need for a second immunology pillar like FB102 to mitigate single‑product dependency.

■86% premium underlines argenx’s willingness to pay for validated clinical data.

■$4.9 Billion cash reserve enables large‑scale deals without financing strain.

■Vyvgart’s dominance may limit near‑term revenue contribution from new assets.

■The Inflation Reduction Act (IRA) continues to tilt investor preference toward biologics over small‑molecule drugs.

Ege Kaan – The FB102 acquisition is more than a growth story; it’s a risk‑balancing maneuver for argenx. With abundant cash, the high‑premium purchase can provide short‑term price support, but investors should re‑price FY 2027‑2028 earnings forecasts around FB102’s potential in non‑oncology autoimmune indications. Considering market volatility and the IRA’s pricing impact, argenx’s stock could target a 12%‑18% upside over the medium term.